Study to Assess Platelet Dysfunction With Verify Now Assay

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01167218
Recruitment Status : Completed
First Posted : July 22, 2010
Last Update Posted : August 10, 2012
Information provided by (Responsible Party):
Nina D'Abreo, MD, Winthrop University Hospital

July 19, 2010
July 22, 2010
August 10, 2012
December 2009
February 2012   (Final data collection date for primary outcome measure)
platelet aggregation defects [ Time Frame: one year ]
to assess platelet aggregation defects
to assess coronary plaque level [ Time Frame: 5 years after radiation tx ]
to compare plaque burden in coronary arteries in patietns who received radiotherapy for left versus right breast cancer
Complete list of historical versions of study NCT01167218 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Study to Assess Platelet Dysfunction With Verify Now Assay
"In-vitro Characterization of Platelet Dysfunction in Common Hematological Disorders Using the Verify Now Assay"
The purpose of this study is to conduct a Verify now assay to detect platelet aggregation defects in patients with Myelodysplastic syndrome(MDS), immune thrombocytopenia purpura (ITP) and myeloproliferative disorders (MPD).
Verify Now is a rapid, simple, point-of service assay to measure platelet aggregation. The verify now assay is designed to assess platelet function based on the ability of activated platelets to bind fibrinogen. It is hoped that this study will detect the subtle platelet functional abnormalities in patients with hematological disorders.
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
patients with platelet defects
Platelet Aggregation Defects
Not Provided
verify now assay
subjects who have Myelodysplastic syndrome, immune thrombocytopenia, and myeloproliferative disorders with platelet disorders
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
February 2012
February 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria

- Patients with common blood disorders such as immune thrombocytopenia purpura(ITP) myelodysplastic syndrome MDS)and myeloproliferative disorders (MPV)

Exclusion Criteria

- Patients with normal platelet counts

Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Nina D'Abreo, MD, Winthrop University Hospital
Nina D'Abreo, MD
Not Provided
Principal Investigator: Nina D'abreo, MD Winthrop University Hospital
Winthrop University Hospital
August 2012